Synergy CHC Corp.
SNYRQ Healthcare Medical Distribution
Synergy CHC Corp.’s revenue for fiscal 2025 (year ended December 2025) was $30.4 million, down 12.8% from fiscal 2024. In the quarter to March 2026, revenue fell 32.8%, EPS fell 330.0%, free cash flow fell 148.5% and total debt rose 7.08%, each against the same quarter a year earlier.
Follow SNYRQ
Synergy CHC Corp. (SNYRQ) EV/Sales
As of 16 October 2026, Synergy CHC Corp. (SNYRQ) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.9× (October 2026) to 2.7× (October 2024) — the current reading is the lowest in ten years. That is above the Medical Distribution industry median of 0.6× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.3× | (11.32%) |
| FY2024 | 1.5× | (44.06%) |
| FY2023 | 2.7× | 0.00% |
| FY2022 | 2.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.4× | 6.39% |
| Dec 2025 | 1.3× | (5.49%) |
| Sep 2025 | 1.4× | (2.94%) |
| Jun 2025 | 1.5× | 13.05% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| YI 111, Inc. Sponsored ADR compare | 0.0× |
| CAH Cardinal Health, Inc. compare | 0.3× |
| COSM Cosmos Health Inc. compare | 0.4× |
| ACH Accendra Health, Inc. compare | 0.9× |
| HSIC Henry Schein, Inc. compare | 0.9× |
| SNYRQ Synergy CHC Corp. | 0.9× |
| AHG Akso Health Group Sponsored ADR compare | 1.8× |
| FOCL FocalTherics compare | 2.1× |
| Medical Distribution industry median | 0.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)